The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group
- Registration Number
- NCT00617474
- Lead Sponsor
- Labbafinejhad Hospital
- Brief Summary
The study hypothesis is that erythropoietin usage after kidney transplantation, in early phase, can improve the outcome for patients and their graft increasing patient and graft survival.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Hb: >8 and <10 gr/dl
- Age: >18 and <55 years
- Cholesterol: <300 mg/dl
- Triglyceride: <400 mg/dl
- First Transplantation
- Protocol of Immunosuppression: CSA + MMF + Prednisolone
- Systolic BP: <14
- Diastolic BP: <9
Exclusion Criteria
- History of specified cardiac disease
- Second Transplantation or more
- Hb: <7gr/dl
- The patient needs to infusion of blood
- Evidence of local or systemic infection, at the time of EPO injection
- Presence of ATN / DGF after transplantation
- Presence of emergent hypertension
- High risk patients ( Like; PRA>50%)
- Past history of hypersensitivity
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Placebo Patients group with anemia that treated by placebo 1 Erythropoietin Group of patient with anemia, that treated by erythropoietin
- Primary Outcome Measures
Name Time Method We will study the well-being of renal function by evaluation of plasma Cr,GFR,PTDA scan & biopsy proven(If it is necessary to prove the rejection)about measuring of patient - graft survival. May,2008
- Secondary Outcome Measures
Name Time Method